Literature DB >> 12522053

Use of vesicular stomatitis virus pseudotypes bearing hantaan or seoul virus envelope proteins in a rapid and safe neutralization test.

Michiko Ogino1, Hideki Ebihara, Byoung-Hee Lee, Koichi Araki, Ake Lundkvist, Yoshihiro Kawaoka, Kumiko Yoshimatsu, Jiro Arikawa.   

Abstract

A vesicular stomatitis virus (VSV) pseudotype bearing hantavirus envelope glycoproteins was produced and used in a neutralization test as a substitute for native hantavirus. The recombinant VSV, in which the enveloped protein gene (G) was replaced by the green fluorescent protein gene and complemented with G protein expressed in trans (VSVDeltaG*G), was kindly provided by M. A. Whitt. 293T cells were transfected with plasmids for the expression of envelope glycoproteins (G1 and G2) of HTNV or SEOV and were then infected with VSVDeltaG*G. Pseudotype VSV with the Hantaan (VSVDeltaG*-HTN) or Seoul (VSVDeltaG*-SEO) envelope glycoproteins were harvested from the culture supernatant. The number of infectious units (IU) of the pseudotype VSVs ranged from 10(5) to 10(6)/ml. The infectivity of VSVDeltaG*-HTN and VSVDeltaG*-SEO was neutralized with monoclonal antibodies, immune rabbit sera, and sera from patients with hemorrhagic fever with renal syndrome, and the neutralizing titers were similar to those obtained with native hantaviruses. These results show that VSVDeltaG*-HTN and -SEO can be used as a rapid, specific, and safe neutralization test for detecting hantavirus-neutralizing antibodies as an effective substitute for the use of native hantaviruses. Furthermore, the IU of VSVDeltaG*-HTN and -SEO did not decrease by more than 10-fold when stored at 4 degrees C for up to 30 days. The stability of the pseudotype viruses allows distribution of the material to remote areas by using conventional cooling boxes for use as a diagnostic reagent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12522053      PMCID: PMC145270          DOI: 10.1128/cdli.10.1.154-160.2003

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  21 in total

Review 1.  Hantaviruses: genome structure, expression and evolution.

Authors:  A Plyusnin; O Vapalahti; A Vaheri
Journal:  J Gen Virol       Date:  1996-11       Impact factor: 3.891

2.  Efficient selection for high-expression transfectants with a novel eukaryotic vector.

Authors:  H Niwa; K Yamamura; J Miyazaki
Journal:  Gene       Date:  1991-12-15       Impact factor: 3.688

3.  Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles.

Authors:  M J Schnell; L Buonocore; E Kretzschmar; E Johnson; J K Rose
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  The interactionof antiody with the major surface glycoprotein of vesicular stomatitis virus. I. Analysis of neutralizing epitopes with monoclonal antibodies.

Authors:  L Lefrancios; D S Lyles
Journal:  Virology       Date:  1982-08       Impact factor: 3.616

5.  Characterization of Hantaan virus envelope glycoprotein antigenic determinants defined by monoclonal antibodies.

Authors:  J Arikawa; A L Schmaljohn; J M Dalrymple; C S Schmaljohn
Journal:  J Gen Virol       Date:  1989-03       Impact factor: 3.891

6.  DNA vaccination with the Hantaan virus M gene protects Hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys.

Authors:  J W Hooper; D M Custer; E Thompson; C S Schmaljohn
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Recombinant vesicular stomatitis viruses from DNA.

Authors:  N D Lawson; E A Stillman; M A Whitt; J K Rose
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

8.  Western blotting using recombinant Hantaan virus nucleocapsid protein expressed in silkworm as a serological confirmation of hantavirus infection in human sera.

Authors:  K Yoshimatsu; J Arikawa; H Li; H Kariwa; N Hashimoto; N Suzuki
Journal:  J Vet Med Sci       Date:  1996-01       Impact factor: 1.267

9.  Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies.

Authors:  J Arikawa; J S Yao; K Yoshimatsu; I Takashima; N Hashimoto
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

10.  Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones.

Authors:  S P Whelan; L A Ball; J N Barr; G T Wertz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

View more
  30 in total

1.  Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.

Authors:  May S ElSherif; Catherine Brown; Donna MacKinnon-Cameron; Li Li; Trina Racine; Judie Alimonti; Thomas L Rudge; Carol Sabourin; Peter Silvera; Jay W Hooper; Steven A Kwilas; Nicole Kilgore; Christopher Badorrek; W Jay Ramsey; D Gray Heppner; Tracy Kemp; Thomas P Monath; Teresa Nowak; Shelly A McNeil; Joanne M Langley; Scott A Halperin
Journal:  CMAJ       Date:  2017-06-19       Impact factor: 8.262

2.  In vitro and in vivo efficacy of a Rift Valley fever virus vaccine based on pseudovirus.

Authors:  Jian Ma; Ruifeng Chen; Weijin Huang; Jianhui Nie; Qiang Liu; Youchun Wang; Xiaoming Yang
Journal:  Hum Vaccin Immunother       Date:  2019-06-20       Impact factor: 3.452

3.  Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses.

Authors:  Mallory Willet; Drishya Kurup; Amy Papaneri; Christoph Wirblich; Jay W Hooper; Steve A Kwilas; Rohan Keshwara; Andrew Hudacek; Stefanie Beilfuss; Grit Rudolph; Elke Pommerening; Adriaan Vos; Andreas Neubert; Peter Jahrling; Joseph E Blaney; Reed F Johnson; Matthias J Schnell
Journal:  J Infect Dis       Date:  2015-06-10       Impact factor: 5.226

4.  Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting.

Authors:  Jean K Millet; Tiffany Tang; Lakshmi Nathan; Javier A Jaimes; Hung-Lun Hsu; Susan Daniel; Gary R Whittaker
Journal:  J Vis Exp       Date:  2019-03-01       Impact factor: 1.355

5.  Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges.

Authors:  Rebecca J Grant-Klein; Louis A Altamura; Catherine V Badger; Callie E Bounds; Nicole M Van Deusen; Steven A Kwilas; Hong A Vu; Kelly L Warfield; Jay W Hooper; Drew Hannaman; Lesley C Dupuy; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Development of novel immunoglobulin G (IgG), IgA, and IgM enzyme immunoassays based on recombinant Puumala and Dobrava hantavirus nucleocapsid proteins.

Authors:  Helga Meisel; Anne Wolbert; Ausra Razanskiene; Andreas Marg; Andris Kazaks; Kestutis Sasnauskas; Georg Pauli; Rainer Ulrich; Detlev H Krüger
Journal:  Clin Vaccine Immunol       Date:  2006-10-04

7.  Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus.

Authors:  Kyle S Brown; David Safronetz; Andrea Marzi; Hideki Ebihara; Heinz Feldmann
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

8.  Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for pH-dependent entry into human and animal cell lines.

Authors:  Heike Hofmann; Xingxing Li; Xiaoai Zhang; Wei Liu; Annika Kühl; Franziska Kaup; Samantha S Soldan; Francisco González-Scarano; Friedemann Weber; Yuxian He; Stefan Pöhlmann
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

9.  Hemorrhagic fever with renal syndrome, Vietnam.

Authors:  Vu Thi Que Huong; Kumiko Yoshimatsu; Vu Dinh Luan; Le Van Tuan; Le Nhi; Jiro Arikawa; Tran Minh Nhu Nguyen
Journal:  Emerg Infect Dis       Date:  2010-02       Impact factor: 6.883

10.  Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with andes virus.

Authors:  David Safronetz; Nagendra R Hegde; Hideki Ebihara; Michael Denton; Gary P Kobinger; Stephen St Jeor; Heinz Feldmann; David C Johnson
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.